BioFluidica

Executive Summary

BioFluidica is a San Diego-based private biotechnology company developing LiquidScan, a fully automated liquid biopsy platform capable of isolating and analyzing multiple biomarkers—including circulating tumor cells (CTCs), exosomes, and cell-free DNA—from a single blood sample. The platform targets ultra-sensitive diagnostics for oncology and prenatal screening, currently available for research use only. Founded in 2007, the company has remained relatively under the radar, suggesting a focus on technology refinement and clinical validation before seeking broader commercialization. Its ability to integrate rare cell capture with molecular analysis in one workflow could differentiate it from single-analyte competitors, addressing the need for comprehensive liquid biopsy solutions. With liquid biopsy markets growing rapidly, BioFluidica's multi-analyte approach positions it to capture value across cancer early detection, monitoring, and prenatal testing—if it can navigate regulatory and commercial hurdles.

Upcoming Catalysts (preview)

• 2027Series B or C Funding Round60% success
• 2026Clinical Partnership with Major Cancer Center40% success
• Q4 2026Publication of Validation Data in Peer-Reviewed Journal70% success